Skip to main content
Log In
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
Basket
Search
More
Search for this keyword
Advanced search
Latest content
Browse by collection
Archive
Authors
About
Search for this keyword
Advanced search
Close
More
Main menu
Latest content
Browse by collection
Archive
Authors
About
Log in
More
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?
BMJ Journals
You are here
Home
Archive
Volume 8, Issue 1
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
Email alerts
Article metrics
Article menu
Article
Text
Article
info
Citation
Tools
Share
Rapid Responses
Article
metrics
Alerts
PDF
XML
Clinical/translational cancer immunotherapy
Original research
A first-in-human phase 1 dose escalation study of spartalizumab (PDR001), an anti–PD-1 antibody, in patients with advanced solid tumors
Online download statistics by month:
Online download statistics by month: March 2020 to March 2024
Abstract
Full
Pdf
Mar 2020
384
384
147
Apr 2020
208
208
75
May 2020
94
94
41
Jun 2020
116
116
49
Jul 2020
70
72
23
Aug 2020
83
83
47
Sep 2020
136
136
32
Oct 2020
115
115
37
Nov 2020
85
86
22
Dec 2020
84
84
37
Jan 2021
109
109
68
Feb 2021
116
116
30
Mar 2021
225
225
65
Apr 2021
185
185
67
May 2021
188
188
49
Jun 2021
167
167
39
Jul 2021
158
158
67
Aug 2021
127
127
28
Sep 2021
128
128
47
Oct 2021
146
147
62
Nov 2021
265
266
74
Dec 2021
139
138
32
Jan 2022
157
163
30
Feb 2022
136
142
32
Mar 2022
164
169
54
Apr 2022
201
208
43
May 2022
202
208
40
Jun 2022
181
191
38
Jul 2022
165
172
35
Aug 2022
161
163
52
Sep 2022
176
191
53
Oct 2022
101
103
32
Nov 2022
131
135
39
Dec 2022
137
140
26
Jan 2023
85
85
20
Feb 2023
138
138
22
Mar 2023
145
146
39
Apr 2023
104
104
22
May 2023
122
122
24
Jun 2023
136
136
31
Jul 2023
100
103
30
Aug 2023
103
103
30
Sep 2023
52
52
19
Oct 2023
46
46
10
Nov 2023
65
65
7
Dec 2023
51
51
27
Jan 2024
51
52
31
Feb 2024
78
78
24
Mar 2024
81
84
157
Total
6597
6682
2105
Read the full text or download the PDF:
Subscribe
Log in
Log in via Institution
Log in via OpenAthens
Log in using your username and password
For personal accounts OR managers of institutional accounts
Username
*
Password
*
Forgot your log in details?
Register a new account?
Forgot
your user name or password?